We have a deep understanding of and experience translating CD206 targeting technology, particularly in the area of radiopharmaceuticals, into novel products to advance patient care. We believe that by applying this underlying technology from our Manocept CD206 targeting platform, Navidea has the potential to develop next-generation targeted therapies for cancer, infectious diseases, autoimmune disorders, and other inflammatory diseases.

Pipeline ImagePipeline Image